<DOC>
	<DOCNO>NCT01437618</DOCNO>
	<brief_summary>The purpose study prospectively verify FOLFOXIRI plus bevacizumab first-line treatment could consider promising approach improve outcome BRAF mutant metastatic colorectal cancer patient</brief_summary>
	<brief_title>First-line FOLFOXIRI Plus Bevacizumab BRAF Mutant Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically confirm colorectal adenocarcinoma ; Availability formalinfixed paraffin embed tumor block primary and/or metastasis ; BRAF V600E mutant status primary colorectal cancer and/or relate metastasis ; Unresectable measurable metastatic disease accord RECIST criterion ; Male female , age &gt; 18 year &lt; 75 year ; ECOG PS &lt; 2 age &lt; 71 year ; ECOG PS = 0 aged 7175 year ; Life expectancy 3 month ; Adequate haematological function : ANC ≥ 1.5 x 10^9/L ; platelet ≥ 100 x 10^9/L , Hb ≥ 9 g/dL ; Adequate liver function : serum bilirubin ≤ 1.5 x ULN ; alkaline phosphatase transaminases ≤ 2.5 x ULN ( case liver metastases ≤ 5 x ULN ) ; Serum creatinine ≤ 1.5 x ULN ; Previous adjuvant chemotherapy allow 12 month elapse end adjuvant therapy first relapse ; At least 6 week prior extend radiotherapy 4 week surgery ; Written inform consent experimental treatment molecular analysis . Presence history CNS metastasis ; Serious , nonhealing wound , ulcer , bone fracture ; Evidence bleed diathesis coagulopathy ; Uncontrolled hypertension ; Clinically significant ( i.e . active ) cardiovascular disease example cerebrovascular accident ( CVA ) ( ≤6 month treatment start ) , myocardial infarction ( ≤ 6 month treatment start ) , unstable angina , NYHA ≥ grade 2 chronic heart failure ( CHF ) , uncontrolled arrhythmia ; Current recent ( within 10 day prior study treatment start ) ongoing treatment anticoagulant therapeutic purpose ; Chronic , daily treatment highdose aspirin ( &gt; 325 mg/day ) ; Symptomatic peripheral neuropathy ≥ 2 grade NCICCTG criterion ; Active uncontrolled infection ; Treatment investigational drug within 30 day prior enrolment ; Other coexist malignancy malignancy diagnose within last 5 year exception curatively treat basal squamous cell carcinoma skin situ cancer cervix ; Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start ; Lack physical integrity upper gastrointestinal tract malabsorption syndrome ; Fertile woman ( &lt; 2 year last menstruation ) men childbearing potential willing use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>